NCT00397228 is a Phase 2 clinical trial of ALTROPANE® in Parkinson Disease, sponsored by Molecular NeuroImaging.

Who is sponsoring NCT00397228?

NCT00397228 is sponsored by Molecular NeuroImaging.

What drugs are being tested in NCT00397228?

Interventions in NCT00397228: ALTROPANE®.

What condition does NCT00397228 study?

NCT00397228 studies Parkinson Disease.

Is NCT00397228 still recruiting?

NCT00397228 is currently completed. Last updated 15 December 2016.

Last reviewed 2016-12-15 · How we verify

NCT00397228

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Completed Phase 2 Last updated 15 December 2016

What this trial tests

Phase 2 trial testing ALTROPANE® in Parkinson Disease in 27 participants. Completed in 1 December 2011.

Timeline

1 November 2006

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Molecular NeuroImaging
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	27
Start date	1 November 2006
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	1 location across United States

Drugs / interventions tested

ALTROPANE®

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Molecular NeuroImaging — full company profile →

Who can join

30 and older, any sex, with Parkinson Disease. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Optimize ALTROPANE® dosing and the image acquisition protocol to develop a quantitative imaging outcome that would enhance ALTROPANE® reliability, ease of use and ease of analysis.
Time frame: 2 years

Sponsor's own description

After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6 weeks of the injection 1.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Molecular NeuroImaging trials

Trials by the same sponsor.

NCT03142724 — Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects · Phase 1 · completed
NCT03082768 — Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects · EARLY_PHASE1 · completed
NCT03058965 — Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain · EARLY_PHASE1 · completed
NCT03876002 — Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00397228 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Molecular NeuroImaging
Last refreshed: 15 December 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00397228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing